Hosoda K, et al. - In this single-institutional phase II trial, researchers investigated the safety and feasibility of robotic distal gastrectomy (RDG) with lymph node dissection for patients with clinical stage IA gastric cancer in the lower two-thirds of the stomach who were considered to be curatively resected via distal gastrectomy. They noted an overall postoperative complications rate of 16%. Requirement for treatment was noted for 0% (90% confidence interval, 0–9.8%) of patients who developed intra-abdominal complications. In-hospital adverse events of grade 3 or higher were not reported in any of the patient. Outcomes thus confirm RDG as a safe treatment option with limitation by the restriction of dedicated surgeons.